NCT05561556: MOVHS

Mitochondria Oxidative Stress and Vascular Health Study

Completed NA Last updated 29 September 2025

What this trial tests

NA trial testing MitoQ in Cardiovascular Diseases in 31 participants. Completed in 26 September 2025.

Timeline

6 December 2022

Primary endpoint
26 September 2025

26 September 2025

Quick facts

Lead sponsor	Auburn University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	basic science
Enrollment	31
Start date	6 December 2022
Primary completion	26 September 2025
Estimated completion	26 September 2025
Sites	1 location across United States

Drugs / interventions tested

• MitoQ — full drug profile →

Conditions studied

• Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
• Hypertension — all drugs for Hypertension →
• Racism — all drugs for Racism →
• Vascular Diseases — all drugs for Vascular Diseases →

Sponsor

Auburn University

Who can join

Adults 45 to 75, any sex, with Cardiovascular Diseases or Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cardiovascular diseases (CVDs) are the number one cause of death in America and most of the post-industrial world. Hypertension is a leading risk factor for CVDs including stroke, myocardial infarction, and heart failure. Black Americans suffer from the highest rates of hypertension of any racial/ethnic group in America, among the highest in the world. There are also well-documented racial disparities in vascular dysfunction (e.g., endothelial dysfunction, arterial stiffening). Thus, racial disparities in hypertension and vascular dysfunction exacerbate the burden of CVDs, with Black Americans being 30% more likely to die from CVD than any other race in the US. It is established that mitochondrial dysfunction contributes to vascular dysfunction. However, there is a knowledge gap regarding whether targeting mitochondrial dysfunction attenuates oxidative stress, vascular dysfunction, and CVD risk among Black adults at heightened CVD risk. Thus, the investigators will conduct an 8-week trial with the mitochondrial antioxidant MitoQ in middle-aged and older Black and non-Black adults. Our overarching hypothesis is that mitochondrial dysfunction contributes to heightened oxidative stress, vascular dysfunction, and higher BP in Black adults; and that MitoQ will attenuate these racial differences. Importantly, the investigators will also assess social determinants of health (e.g., income, neighborhood disadvantage, discrimination) and health behaviors (e.g., diet, physical activity) and uncover their role in oxidative stress, vascular function, and BP Regarding methodology, the investigators will perform blood draws, vascular testing, preceding and following an 8-week, 20mg daily consumption of MitoQ and placebo. The investigators will also measure urine biomarkers of kidney function and blood pressure in adults (45-75 years old).

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

1. Mitochondrial dysfunction: mechanisms and advances in therapy.
   Zong Y, Li H, Liao P, Chen L, et al · · 2024 · cited 614× · PMID 38744846 · DOI 10.1038/s41392-024-01839-8
2. Multifaceted functions of Drp1 in hypoxia/ischemia-induced mitochondrial quality imbalance: from regulatory mechanism to targeted therapeutic strategy.
   Hao S, Huang H, Ma RY, Zeng X, et al · · 2023 · cited 28× · PMID 37833768 · DOI 10.1186/s40779-023-00482-8
3. The Therapeutic Strategies Targeting Mitochondrial Metabolism in Cardiovascular Disease.
   Huang X, Zeng Z, Li S, Xie Y, et al · · 2022 · cited 14× · PMID 36559254 · DOI 10.3390/pharmaceutics14122760
4. Socioeconomic status as a potential mediator of arterial aging in marginalized ethnic and racial groups: current understandings and future directions.
   Darvish S, Mahoney SA, Venkatasubramanian R, Rossman MJ, et al · · 2024 · cited 8× · PMID 38813611 · DOI 10.1152/japplphysiol.00188.2024
5. Mitochondrial Integrity Is Critical in Right Heart Failure Development.
   Müller M, Donhauser E, Maske T, Bischof C, et al · · 2023 · cited 8× · PMID 37446287 · DOI 10.3390/ijms241311108